🔗 Share this article

Given that America undertakes sweeping adjustments to its vaccination schedules, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by questioning COVID-19 vaccines in the pandemic and has focused upon potential fatalities after COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Schedule

Agency leaders were set to reveal sweeping revisions to the childhood immunization program recently, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US out of alignment with a large portion of the international standard with no evidence for improved outcomes. The announcement has been postponed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A New Direction at the FDA

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a nation with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible background in pharmaceutical research, oversight or administrative roles, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in leading a major agency. She lacks background in drug approvals.”

Former heads of CBER would “be deeply familiar with legal statutes and the underlying principles of drug development”, commented Janet Woodcock. “Frankly, she doesn’t have the type of experience that former directors who led CBER have had.”

This division has an immense workload at the FDA, she emphasized.

“The public just zeroes in on the innovative therapies, but the generic program authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and every single one have to be supervised,” she said. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major leadership element to the job, which oversees more than 5,000 staff members. “It is a massive administrative position, if you perform it correctly,” Woodcock said.

Official Statement and Controversial Initiatives

When asked about questions about Høeg’s credentials and whether this selection indicates greater collaboration among FDA leaders on immunizations, a spokesperson stated that the “concerns stem from inaccurate assumptions”.

“Her experience matches the functions of her position,” the spokesperson said, citing the months Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a contentious rapid drug-approval program that allegedly worried her former heads. “How are these drugs being picked for this fast-track system? Who makes the choices?” Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, with the exception of vaccines.”

Established Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if troubling, past, some experts have noted. She published a analysis using non-validated crowd-sourced reports to assess the rate of myocarditis following Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Among her “desired changes” for the current federal leadership encompassed altering rules for recently developed shots and ending “unnecessary” immunizations, she stated following the vote on a online show. At the agency, Dr. Høeg has allegedly proposed preventing young men from receiving COVID-19 vaccines.

“She’s an complete ideologue who starts off with her beliefs and works backwards to retrofit the science in a highly misleading, dishonest fashion,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|